Boccardi M	FIS_71375
Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe.
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update.
Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics.
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison.
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.